Immune Checkpoint Inhibition in Advanced Cancer Treatment

Immune checkpoint inhibitors have transformed the management of advanced malignancies by releasing the brakes on antitumour T-cell responses. Agents targeting programmed cell death protein 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have produced durable remissions across diverse tumour types, including melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma. Current research focuses on overcoming primary and acquired resistance through combination regimens—pairing checkpoint blockade with targeted therapies, radiation or personalised cancer vaccines—and on refining patient selection via immune profiling. Advances in single-cell sequencing and spatial transcriptomics are revealing the cellular states and microenvironmental cues that underlie response or failure. Parallel efforts aim to optimise treatment duration, mitigate immune-related toxicity and extend benefit to less-immunogenic cancers. Together, these developments promise to consolidate checkpoint inhibition as a cornerstone of precision oncology.

Research from Nature Portfolio

Recent studies have harnessed high-resolution profiling of tumour–immune interfaces to stratify responders and non-responders on the basis of T-cell exhaustion signatures and myeloid suppressive networks. One report demonstrated that co-targeting LAG-3 alongside PD-1 reinvigorates exhausted T cells and improves tumour control in models resistant to single-agent blockade. Another investigation employed epigenetic remodellers to reprogramme the chromatin landscape of dysfunctional T cells, enhancing the efficacy of PD-1 inhibition in preclinical solid tumours. A third advance described the development of bispecific antibodies that concurrently engage PD-1 and novel checkpoint molecules, producing synergistic antitumour immunity with a favourable safety profile.

Immune Checkpoint Inhibition in Advanced Cancer Treatment publication trend

The graph below shows the total number of articles in immune checkpoint inhibition in advanced cancer treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Programmed cell death protein 1 (PD-1): An inhibitory receptor on activated T cells that dampens immune responses when engaged by PD-L1 or PD-L2.

PD-L1: A ligand expressed on tumour and immune cells that binds PD-1, leading to T-cell inactivation.

CTLA-4: A checkpoint receptor upregulated on T cells that competes with the costimulatory receptor CD28, limiting T-cell activation.

Tumour microenvironment: The complex milieu of cancer cells, immune infiltrates, stromal elements and signalling molecules that influences tumour growth and therapy response.

Treatment-free survival (TFS): A metric measuring the duration during which patients remain off subsequent systemic therapy without disease progression, reflecting sustained benefit and quality of life.

References

1. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Molecular Cancer (2020).
2. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology (2019).
3. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. BMC Cancer (2021).